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Summary 
Aim: Medication review has been advocated as one of the measures to tackle the challenge of 
polypharmacy in older patients, yet there is no consensus on how best to evaluate its efficacy. This 
study aimed to assess outcome reporting in trials of medication review in older patients.  
Methods: Randomized controlled trials (RCTs), prospective studies and RCT protocols involving 
medication review performed in patients aged 65 years or older in any setting of care were 
identified from: (1) a recent systematic review; (2) RCT registries of ongoing studies; (3) the 
Cochrane library. The type, definition, and frequency of all outcomes reported were extracted 
independently by two researchers.  
Results: 47 RCTs or prospective published studies and 32 RCT protocols were identified. A total of 
327 distinct outcomes were identified in the 47 published studies. Merely one fifth (21%) of the 
studies evaluated the impact of medication reviews on adverse events like adverse drug reactions or 
drug-related hospital admissions. Most of the outcomes were related to medication use (n=114, 
35%) and healthcare use (n=74, 23%). Very few outcomes were patient related outcomes (n=24, 
7%). A total of 248 distinct outcomes were identified in the 32 RCT protocols. Overall, the number of 
outcomes and the number and type of health domains covered by the outcomes varied largely. 
Conclusion: Outcome reporting from RCTs concerning medication review in older patients is 
heterogeneous. This review highlights the need for a standardised core outcome set for medication 
review in older patients, to improve outcome reporting and evidence synthesis.  
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Introduction 
Older patients are often exposed to polypharmacy [1,2]. This increases the risk of adverse drug 
reactions (ADR) and the cost of medications [3–6]. Performing a medication review has been shown 
to be an efficient approach to optimise the quality of prescriptions in older patients [7,8]. 
Medication review has been defined by the NICE guidelines as “a structured, critical examination of 
patient’s medicines with the objective of reaching an agreement with the patient about treatment, 
optimising the impact of medicines, minimising the number of medication related problems and 
reducing waste” [9]. 
Numerous randomized controlled trials (RCT) have been performed to evaluate the impact of 
medication review on clinical, patient reported, and economic outcomes. Several systematic reviews 
and meta-analyses have therefore been conducted to summarize the effectiveness of medication 
review in various settings [7,8,10–20]. However, the heterogeneity of outcomes reported in the RCTs 
has limited the quality of the conclusions of these systematic reviews. Robust meta-analyses could 
be performed for only a few outcomes, including hospitalisation and death [15–17,21]. For other 
outcomes, results were essentially summarized in a descriptive way because of heterogeneity in the 
choice and definition of the outcomes [17–20,22].  
Outcome reporting bias is an under-recognised problem that affects the conclusions in a substantial 
proportion of systematic and Cochrane reviews [23–25]. This bias has been defined as selection (on 
the basis of the results) of a subset of the original variables recorded for inclusion in a study 
publication [26]. In a large unselected cohort of Cochrane systematic reviews, more than half of the 
reviews did not include full data for the review primary outcome of interest from all eligible trials 
[23]. Consequently, the updated Consolidated Standards of Reporting Trials (CONSORT) statement 
has recently recommended the use of identified and well defined outcomes in RCTs. In other fields 
of medicine, authors have conducted systematic reviews to reveal and quantify the heterogeneity 
and inconsistency of outcome reporting in a given research area [27–30]. According to the OMERACT 
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(Outcome Measures in Rheumatology) and the COMET (Core Outcome Measures in Effectiveness 
Trials) guidelines, some of these works have led to the development of core outcomes sets designed 
to increase the quality of outcome reporting and evidence synthesis in future research [31,32]. 
The purpose of this review was to undertake an in-depth analysis of outcome reporting to identify 
potential heterogeneity in outcomes reported from RCTs and prospective studies of medication 
review in older patients. 
 
Methods 
Study selection 
We considered RCT, quasi-RCT, and other prospective interventional studies which investigated the 
effect of medication review performed in patients aged 65 years or older [33]. This age limit was 
widely used in trials of medication review during the last decades and corresponds to the WHO age 
limit to define older people. The following studies were excluded: studies published before 2000; 
studies predominantly including patients younger than 65 years old; retrospective studies; no 
outcome reported; sample size lower than 50 participants; medication reviews for a specific disease 
or condition (e.g. chronic heart failure) or as part of a multifaceted approach. By multifaceted 
approach we meant a complex intervention which contained additional interventions to the 
medication review (e.g. physiotherapy, nutritional advice, occupational therapy). 
Search strategy 
We performed a systematic review of published studies. Our starting point was the systematic 
review published in 2014 by Lehnbom et al. [10], which purpose was to examine the evidence 
regarding the effectiveness of medication review to improve clinical outcomes. Lehnbom et al. 
identified 43 studies published before March 2014 [10].  As the purpose of the present systematic 
review was different in nature, we only used the result of the search strategy, i.e. the list of the 
published studies included in the systematic review. Only the studies complying with our inclusion 
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and exclusion criteria were included. In addition, an update of the literature search using the same 
strategy/queries was performed for the period of March 2014 and July 2015 (the search strategy 
from [10] is given in supplementary data). Two reviewers (LP and JBB) independently assessed the 
title and abstracts of studies resulting from the searches. Full texts were investigated for all eligible 
published studies by two independent reviewers (LP and JBB). Any disagreement on the inclusion of 
a study was resolved by discussion and consensus. A third reviewer (AS) was involved if needed. 
In addition, we used the search terms from the systematic review to identify RCTs protocols related 
to medication review on the following RCT websites: WHO international clinical trials registry 
platform: http://apps.who.int/trialsearch/; EU Clinical Trials Register: 
https://www.clinicaltrialsregister.eu/ctr-search/search; US Clinical Trials register: 
https://clinicaltrials.gov. Two independent reviewers (BB and JBB) first assessed the titles and 
subsequently the summaries of the RCTs protocols identified by the queries. Any disagreement on 
the inclusion of a study was resolved by discussion and consensus. A third reviewer (AS) was 
involved if needed. It was verified if protocols had matured to full report publications. If this was the 
case, the paper was evaluated as mentioned above and added to the set of published studies. 
Finally, the search terms from the systematic review were also used to identify relevant Cochrane 
reviews. A reviewer (JBB) identified the relevant Cochrane systematic reviews and then extracted 
the eligible original studies in the selected Cochrane systematic reviews. The selection process was 
checked by a second reviewer (AS).  
Data extraction 
An electronic data extraction form was developed with Epidata® software and pilot tested to 
increase the reliability of the data extractions. All data extractions on outcomes and outcome 
measurement instruments were performed by two independent reviewers (ST and JBB for RCT 
protocols; LP and JBB for published studies). Any disagreement was resolved by discussion and 
consensus. A third reviewer (AS) was involved if needed. 
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The characteristics of the RCT protocols and the published studies were extracted by one reviewer 
(JBB) and included: setting (hospital setting, primary care, nursing home); number of patients 
intended to be recruited (RCT protocols) or actually included (published studies); mean age 
(published studies only). 
Outcomes used to compare the two groups under investigation (in RCTs and prospective 
before/after studies) or to evaluate the medication review process were extracted: name of the 
outcome in free text (what was measured in published studies and what was planned to be 
measured in protocols); primary or secondary outcome. For each outcome, the following data about 
measurement instrument were extracted from published studies: which instrument was used to 
measure the outcome (free text); was the method of measurement clearly defined (the reviewer 
answered “Yes” if he/she believed that another researcher could reproduce the procedure and its 
measurement with the explanations provided in the methods section). As the data provided in RCT 
protocols are often less detailed than in published studies, the data on measurement instrument 
were extracted when available. 
Classification of outcomes into heath domains and subdomains 
The classification of the outcomes extracted from the included studies was achieved in several steps. 
Firstly, a list of 19 pre-defined subdomains corresponding to the most frequently reported outcomes 
(e.g. hospitalisation, all-cause death) were identified from the systematic review updated in this 
study [10]. These pre-defined subdomains were used by the two reviewers to associate each 
extracted outcome to a subdomain. The reviewers were free to propose a new subdomain if an 
outcome did not fit with the proposed subdomains. Secondly, a new list of subdomains was drafted 
on the basis of the pre-defined and the newly proposed subdomains. A consultation exercise was 
then performed with experts in clinical pharmacy and geriatricians. The objective was to get 
consensus on subdomain terms, to avoid major overlaps between subdomains, and to aggregate 
subdomains into health domains. The OMERACT filter 2.0 was used to organise this classification. A 
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total of 57 subdomains were identified and grouped into eight health domains (supplementary data; 
eTable 1). 
Analysis 
Quantitative variables were described by median, first and third quartiles (Q1, Q3), minimum and 
maximum because of skewed distributions. Qualitative variables were expressed as frequencies and 
percentages. 
Results 
Selection of studies and RCT protocols  
In total, 47 published studies [34–80] and 32 RCT protocols were included in this systematic review. 
Details on the sources, reasons for exclusion, and selection process are presented in Figure 1. 
Characteristics of the studies and RCT protocols included for data abstraction 
The characteristics of the published studies and the RCT protocols included for data abstraction are 
provided in Table 1. The median number of participants included in published studies and intended 
to be included in RCTs described in protocols were similar. The studies were performed mainly in 
Europe, followed by Australia and USA. More recent RCT protocols have mainly been developed in 
European countries. The median number of outcomes per study or per RCT protocol was seven. This 
number varied importantly, from a single outcome in a published study [69] to 19 distinct outcomes 
in a RCT protocol [81].  
Outcomes identified in the published studies and RCT protocols 
The published studies and RCT protocols covered a median of four of the eight health domains 
identified (range: 1 to 6 for published studies; 2 to 7 for RCT protocols). The results are summarised 
in Figure 2 and detailed per sub-domains in eTable 2. More than 50% of all outcomes reported in 
published studies concerned medication use (e.g. the number of drugs, the number of potentially 
inappropriate medications, or overuse) or healthcare use (e.g. hospitalisations or GP visits). Other 
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health domains like patient reported outcomes, geriatric syndromes, or costs evaluation were far 
less frequently investigated. Only one fifth (21%) of the 47 published studies have evaluated the 
impact of medication reviews on adverse events such as ADR or drug-related hospital admissions. 
Consequently, less than one in ten published studies (n=4; 9%) had a primary outcome in the 
adverse event domain. 
Outcomes related to medication use were reported by 89% of published studies and 94% of RCT 
protocols, suggesting an informal consensus on reporting this health domain. However, there was 
substantial variation in the subdomains used to explore this health domain between studies. Twelve 
different subdomains were identified and variously measured in the studies.  The number of studies 
using each subdomains varied from only one time (“anticholinergic drug use” in 1 RCT protocols) to 
26 times (“number of drugs” in 17 published studies and 9 RCT protocols). Eight of these 12 
subdomains were used at least once as a primary outcome in a published study or in a RCT protocol.  
This between-subdomain heterogeneity was also observed for the seven other health domains, as 
detailed in eTable 2. For example, seven, 10, and 12 different subdomains were variously used to 
explore the healthcare use, patient-reported outcome, and geriatric syndromes domains, 
respectively. In total, nearly half of the subdomains (n=28; 49%) were used by less than 10% of the 
79 selected studies (published studies and RCT protocols). Conversely, only four subdomains were 
used by a third or more of the 79 selected studies, namely “number of drugs”, “hospitalisation”, “all-
cause death”, and “health-related quality of life”.  
Clarity of measurement instrument reported 
The total number of outcomes and the specific number of outcomes for which an instrument 
measurement was clearly described in the methods are presented per health domain in Table 2 and 
per subdomain in supplementary data (eTable 3). In total, the measurement instruments were 
considered clearly reported in 52% to 83% of all domains, except for cost outcomes. In the costs 
domain, the methods most often insufficiently described the source of drug costs or costs related to 
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healthcare use, or the way in which calculations were performed. For medication use, the methods 
were considered clear in two thirds (65%) of the outcomes. The outcomes most often considered 
poorly defined were the outcomes “Number of drugs”, and “Drug-drug interactions”.  
Discussion 
This systematic review provides an analysis on which health domains have been and are currently 
evaluated in published and planned/ongoing studies (RCT protocols) of medication review in older 
patients. It reveals that there is substantial heterogeneity, as the number of outcomes and the 
number and type of health domains covered by the outcomes vary from one study to another. 
Furthermore, it shows that some essential health domains including adverse events and patient 
related outcomes have been poorly evaluated in published studies. These results highlight the need 
for developing a core outcome set for medication review in older patients. Having strong outcome 
data would help clarifying if and how medication review can be effective, among which population, 
in which context, and what are the important contextual factors which support positive outcomes. 
Not surprisingly, our results have shown that most studies of medication review in older patients 
have reported, or planned to report, outcomes related to the medication use domain. These 
outcomes were often the primary outcomes. However, the 13 distinct subdomains identified in the 
medication use domain were variously used by authors (eTable2). Despite this heterogeneity 
between subdomains, several systematic reviews of RCTs have tried to summarize the effect of 
medication review on such outcomes. Their results showed that medication review is effective in 
improving drug appropriateness, drug underuse, or potentially inappropriate prescribing, but there 
were more conflicting results for drug-related problems [7,8,18,20]. Evaluating the effects of 
medication review on more specific outcomes such as inappropriate use of antipsychotic drugs was 
limited due to inconsistency in the various definitions of the outcome used across the studies [22]. 
We identified that clarity in the reporting of the measurement instruments in some domains varied 
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substantially and this impacts upon the extent to which the outcomes from such studies can be 
accurately interpreted, and may limit the validity of comparison of results across studies. 
Our results also show that many published studies have reported outcomes related to the use of 
healthcare resources domain, mainly hospitalisations. Meta-analyses however have failed to identify 
a significant effect of medication review on hospital admissions, length of hospital stays, or 
emergency department visits [12,15–17,21,82]. These negative results may have discouraged new 
studies to use this outcomes as a primary outcome. One hypothesis is that these outcomes are 
influenced by many other factors, which could explain why this outcome is less often used as 
primary outcome in RCT protocols.  
Ten (21%) published studies reported outcomes related to the adverse events domain. This may be 
due to the difficulty in detecting and adjudicating adverse events prospectively during an RCT. 
Hence, the effects of medication review on ADR or drug-related hospital admissions remain unclear 
and have not been assessed by any meta-analysis. Reporting bias of harm outcomes in RCTs and 
systematic reviews has been identified as an important problem [83]. It seems particularly 
detrimental that harm outcomes have been so poorly reported in RCTs of medication review, as the 
purpose of this intervention is actually to manage the risk of prescribed drugs and to reduce the 
number of drug-related problems. A higher proportion of on-going studies planned to report adverse 
events according to their protocols. However, it is uncertain whether this greater focus on these 
outcomes in protocols will be released in the final studies’ results. Outcomes related to costs were 
also less extensively investigated. The effect of medication review on costs is therefore most often 
analysed through a narrative approach in systematic reviews [13,20]. 
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Patient reported outcomes have been investigated in 43% of published studies and are planned to 
be investigated in 69% of RCT protocols. Most of these outcomes concern health-related quality of 
life (eTable 2). Very few studies have investigated or will investigate subdomains like drug-regimen 
complexity or the alignment of drug regimen with patient preference, although these aspects are 
included in the definition of a medication review [9]. 
Several systematic reviews of medication review identified that inconsistency and imprecision in 
outcome reporting limited their analyses and conclusions [13,14,17,18,20,22]. Our present review 
has confirmed and extended these findings. While other systematic reviews aimed at pooling and 
summarizing results on a limited number of outcomes, we have extracted and reported all kinds of 
outcomes used in this field. Several authors have used hospitalisation or mortality to assess the 
clinical effectiveness of a medication review [12,15,16,21]. However, our results suggest that the 
choice to perform meta-analyses on these outcomes are most likely related to the high proportion of 
studies reporting these outcomes as opposed to their relevance. In fact, hospitalisation or death in 
older patients with polypharmacy and multimorbidity can be related to many factors other than 
medications [84,85]. Incidence of ADR or drug-related hospital admissions may be more relevant to 
assess the effectiveness of a medication review, but it is indeed much more difficult and time-
consuming to detect and adjudicate properly all ADEs or drug-related hospital admissions during a 
RCT than to record all-causes hospitalisations or mortality.  
In summary, our results highlight the need for a core outcome set (COS) for future studies of 
medication review in older patients. A COS is an agreed standardised collection of outcome variables 
which should be measured and reported in all trials for a specific condition or clinical area. The 
development of a COS would tackle the challenge of obtaining a consensus on which outcomes are 
deemed essential for all stakeholders involved in the management of a given condition, including 
patients. It has the potential to reduce heterogeneity between trials, lead to research that is more 
likely to measure relevant outcomes, and enhance the value of evidence synthesis by reducing the 
risk of outcome reporting bias and ensure that all trials report usable information [86–88]. 
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Moreover, in a second step, the measurement instrument recommended to be used to evaluate 
each outcome included in the COS can be determined [89]. This aspect may be important as our 
study has shown that the methods were not clearly detailed in a significant proportion of studies for 
all categories of domains and subdomains. A consensus on the measurement instrument has also 
the potential to increase the quality of value of evidence from subsequent systematic reviews and 
allowing meaningful meta-analyses to be performed. As part of the European Commission-funded 
OPERAM project, this systematic review will serve as a starting point to developing a COS for clinical 
trials of medication review in older patients.  The OPERAM project will perform a multicentre 
randomised controlled trial to assess the impact of an intervention to optimise pharmacotherapy 
and to enhance compliance in 1900 multimorbid patients aged 70 years and older. In order to tackle 
the challenge of measuring relevant outcomes for these patients, the OPERAM project included the 
development a COS suitable for all settings. 
Some limitations of this review should be mentioned. As the aim of this project was of descriptive 
nature, we did not perform analytical analyses to formally compare results from published studies 
and protocol, and had a too low number of studies to evaluate if the between study variation could 
be partially explained by the setting (hospitalised versus nursery home versus community dwelling). 
This systematic review stopped in July 2015, more than one year before its submission. However, 
the variation in outcome reporting between published studies should not have changed considerably 
and has been captured indirectly through the analysis of RCT protocols. It seems therefore unlikely 
that an updated version would have impacted on the results. The selection criteria were those from 
the initial systematic review by Lehnbom et al. [10], which could have influenced the outcomes 
identified. For example, smaller studies with less than 50 subjects, which were excluded from the 
review, may have reported outcomes that require detailed review of patients or records, such as 
ADRs or drug-related admissions, more often. Variation between studies was investigated 
descriptively at the subdomain level but we didn’t report variation between outcomes in a given 
subdomain. The outcomes may vary in a subdomain in the way they were reported (e.g. number of 
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potentially inappropriate medications per patient or number of patients with at least one potentially 
inappropriate medication) or in the way they were measured (e.g. Beers criteria, STOPP criteria, 
PRISCUS list). Another limitation is that the categorization into domains and subdomains may be 
somehow arbitrary. We were also reliant upon the descriptions of domains and measures in the 
published studies and, as we identified, at times these were not clearly described. We used a 
consultation exercise as other studies or study protocols have [30,90], as we could not identify  an 
existing framework to guide this process.  
Conclusion 
This systematic review revealed a significant heterogeneity in outcome reporting in studies of 
medication review in older patients. Some essential health areas including adverse events and 
patient reported outcomes have been insufficiently evaluated. We advocate the development of a 
COS to improve the quality of outcome reporting and evidence synthesis in future research in this 
important field.  
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Figure 1: Flowchart of included studies and RCT protocols. 
Abbreviations: RCT: Randomized controlled trials; MRev: Medication Review; SR: Systematic review 
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Figure 2: Percentage of health domains covered by the 47 published studies and 32 RCT protocols 
included in the systematic review, according to the outcomes identified. The percentage of studies in 
which the domain was covered by a primary outcome is given in darker colour. 
Abbreviations: HC: healthcare; Pub. St.: published studies; St. Pr.: study protocols 
For the full list of subdomains contained in each domain, please refer to eTable 1. 
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Table 1: Summary characteristics and demographics of included studies (published studies included 
35 randomized controlled trials and 12 prospective studies). 
 
 
 
 
 
 Published studies 
(n=47) 
RCT protocols 
(n=32) 
Number of study participants   
 Median 334 300 
 Interquartile range [170; 568] [195; 600] 
 Range [50; 7202] [50; 3685] 
    
Average age   
 Median 80  
 Interquartile range [75.7; 82.7]  
 Range [73.5; 86.8]  
    
Setting   
 Hospital 15 (32%) 11 (34%) 
 Community  19 (40%) 16 (50%) 
 Nursing homes 13 (28%) 5 (16%) 
    
Country   
 EU 28  
(Belgium 2; Denmark 3; 
Germany 1; Ireland 3; The 
Netherlands 1; Spain 2; 
Sweden 5; UK = 11) 
25 
(Belgium 2; France 1; Germany 7; 
Ireland 2; Italy 1; Netherlands 6; 
Norway 1; Slovenia 1; Spain 1; 
Sweden 1; Europe MC 1) 
 Australia 8 3 
 USA 7 1 
 Others 4 3 
    
Year of publication   
 2000 – 2005 14 (30%)  
 2006 – 2010 6 (13%)  
 2011 – 2015  27 (57%)  
    
Number of outcomes   
 Median 7 7 
 Interquartile range [5; 10] [6; 9] 
 Range [1; 14] [2; 19] 
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Table 2: Number of outcomes per health domain with the clarity of the measurement instrument 
used to measure them, as identified in the published studies or in RCT protocols.  
 
  Outcomes   
Measurement 
reproducible* 
 
 
Published 
studies 
(317 outcomes) 
  
RCT  
protocols 
(240 outcomes) 
  
Published 
studies  
RCT 
protocols 
n %(a)   n %(a)   n %(b)   N %(b) 
Medication use 99 31% 
 
51 21% 
 
64 65% 
 
22 43% 
Use of HC resources 70 22% 
 
44 18% 
 
43 61% 
 
6 14% 
Adverse events 11 3% 
 
17 7% 
 
8 73% 
 
10 59% 
Death 18 6% 
 
11 5% 
 
13 72% 
 
2 18% 
Patient reported outcomes 32 10% 
 
38 16% 
 
20 63% 
 
31 82% 
Geriatric syndrome 24 8% 
 
42 18% 
 
20 83% 
 
29 69% 
Costs 21 7% 
 
16 7% 
 
7 33% 
 
4 25% 
Process evaluation 42 13% 
 
21 9% 
 
22 52% 
 
3 14% 
                        
 
Abbreviations: HC: healthcare 
a) Based on the total number of identified outcomes (n = 317 for published studies; n = 240 for RCT protocols) 
b) Based on the total number of outcomes identified in the given domain (value is “n” of the column “Outcomes”) 
* The method of measurement was considered clearly defined if the reviewer believed that another author could 
reproduce the procedure and its measurement with the explanations given in the method section. 
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